Ionis Pharmaceuticals Projects 2026 Revenue Between $875M and $900M Amid Lowered TRYNGOLZA Outlook
Ionis Pharmaceuticals (IONS) provided updated financial guidance for 2026, projecting total revenue in the range of $875 million to $900 million. CEO Brett Monia noted that the company continues its transition into a commercial-stage biotechnology firm, having achieved several key milestones through the first three quarters of 2026. Despite the overall positive revenue outlook, management lowered the sales forecast for TRYNGOLZA to approximately $50 million for the 2026 fiscal year. This adjustment reflects a more conservative expectation for that specific product's market performance within the company's broader commercial portfolio.
Tickers: $IONS
Topics: biotechnology earnings report management commentary revenue guidance